Shorter, stronger radiation for prostate cancer shows promise in new trial

NCT ID NCT03987386

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a shorter, higher-dose radiation schedule (hypofractionated) works as well as the standard longer course for men with prostate cancer who have had surgery. About 186 men will be randomly assigned to one of the two radiation plans. The study tracks side effects, cancer control, and quality of life to see if the shorter approach is safer and just as effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Radiation therapy (hypofractionated vs. conventional)
What this could lead to
If successful, this could offer a more convenient, shorter course of radiation after prostate cancer surgery with fewer side effects.
What could go wrong
This is a mid-stage trial with 186 participants, so results may not apply to all patients. The higher-dose approach could also increase some side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE I PROSTATE CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • MD Anderson League City

    League City, Texas, 77573, United States

  • MD Anderson in Sugar Land

    Sugar Land, Texas, 77478, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.